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78 The Journal of Thoracic and Cardioackground: A stentless valve is expected to be hemodynamically superior to a
tented valve. The aim of this study was to compare early postoperative hemody-
amic function and clinical events in a randomized, prospective series of 160
tentless and stented biological replacement aortic valves.
ethods: We randomized 160 consecutive patients on 1 surgeon’s list to receive
ither a Toronto stentless porcine valve (St Jude Medical, Inc, St Paul, Minn) or a
erimount stented bovine pericardial valve (Edwards Lifesciences, Irvine, Calif).
chocardiography was performed at discharge, between 3 and 6 months, and at 1
ear after surgery. Statistical analysis was performed by both intention to treat and
ctual valves implanted.
esults: The mean labeled size of both designs of valve was 24.7. There were no
tatistically significant differences in results at any time interval or whether analysis
as performed by actual valves implanted or intention to treat. At 3 to 6 months for
he Toronto versus the Perimount valve, the effective orifice area was 1.58 versus
.66 cm2, the mean pressure difference was 7.54 versus 7.42 mm Hg, and the peak
elocity was 2.07 versus 2.0.1 m/s. There was no difference in mortality, regression
f left ventricular hypertrophy, or complications other than paraprosthetic regurgi-
ation at 12 months or on follow-up for a proportion of the sample to 8 years. The
ncidence of regurgitation through the valves was similar for Toronto (10%) and
erimount (13.8%) at 1 year, but mild paraprosthetic regurgitation was found in 5
atients with the Perimount valve and none with Toronto valves.
onclusions: There were no significant differences in hemodynamic function or
linical events between the stented and stentless biological valves chosen for
omparison in the early postoperative period or in preliminary follow-up to 5 years.
ll stented biological replacement valves are relatively obstructive compared
with normal native valves.E1 This could limit or delay regression of left
ventricular (LV) hypertrophyE2 or contribute to mortality and impaired
unctional recovery after aortic valve surgery. An improvement in hemodynamic
unction is one of the main benefits expected from stentless valves. Because these
ack both stents and a sewing ring, there should be a larger orifice available for flow.
In an early nonrandomized comparison using historical control data, the Toronto
tentless valve was shown to be superior to a Hancock II stented porcine valve
Medtronic, Inc, Minneapolis, Minn) at every labeled size.E3 This result was
onfirmed in some,E4 but not all, consecutive nonrandomized studies.E5 Random-
zed studies also show conflicting results, some in favor of stentless valvesE2,E6 and
thers showing no significant difference in hemodynamic function.E7 These dis-
vascular Surgery ● April 2006
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CDrepancies may partly be caused by a failure to correct for
ow. It may also be inappropriate to compare valves of the
ame labeled size because these may differ in actual size.E8
urthermore, involvement of more than 1 surgeon intro-
uces the possibility of uncontrolled procedural variability.
he aim of this study was, therefore, to compare early
ow-corrected hemodynamic function, LV mass regression,
nd clinical results in a single surgeon’s series of patients
rospectively randomized to either a stentless or stented
alve.
ethods
atients
total of 160 consecutive patients scheduled to have single
ioprosthetic valve replacement in the aortic position were ran-
omized. The mean age was 72 years (range, 54-85 years), and 82
51%) were male. The native disease necessitating operation was
ominant aortic stenosis in 132, dominant regurgitation in 16,
ixed disease in 5, and a failing replacement valve in 7. Coexis-
ent coronary bypass grafting was performed in 56, and aortic root
eplacement in 1 (Table 1). The first patient underwent operation
n September 19, 1995, and the last did so on December 17, 2002.
he study was accepted by the Local Committee on Ethical Prac-
ice, and all patients gave written consent.
urgery
he Toronto stentless valve (St Jude Medical, Inc, St Paul, Minn)
onsists of a preparation of porcine aortic root sculpted to accom-
odate the coronary ostia and lined externally with Dacron (Du-
ont, Wilmington, Del). Sizing was undertaken at the sinotubular
unction, as discussed by David and colleagues.E9 Aortoplasty or
nlargement of the sinotubular junction was not required. Implan-
ation was at the level of the annulus, with the lower suture line in
circle joining the lower midpoints of previous cuspal attachment
nd passing across the intercommissural triangles. The porcine
ommissures were suspended independently, and a running
olypropylene suture was used for both the lower and upper suture
ines. The Perimount valve (Edwards Lifesciences Inc, Irvine,
alif) is composed of bovine pericardium mounted in a polypro-
ylene stent with a sewing cuff. It was implanted with continuous
utures, which tended to position it in a supra-annular position.
The patients were randomized at the time of listing for opera-
ion by using a random number sequence with a block of 16.
owever, 11 patients did not receive the valve assigned by ran-
omization. Three patients randomized to a Perimount received a
oronto because of annular destruction. Eight patients randomized
o a Toronto received a Perimount because of severe aortic calci-
cation, sinotubular diameter more than 10% larger than the an-
ulus diameter, or difficult access as a result of adhesions. As a
onsequence, a total of 75 patients actually received a Toronto and
Abbreviation and Acronym
LV left ventricular5 received a Perimount valve. Sizing was performed for both (
The Journal of Thoracicesigns of valve, and the valve size that would have been im-
lanted had the other valve been randomized was noted.
chocardiography
tudies were performed immediately before discharge, between 3
nd 6 months after surgery, and at 1 year (range, 10-14 months).
nly 140 patients (66 with a Toronto and 74 with a Perimount)
ere studied at 3 to 6 months because 10 had died, 8 allowed
ollow-up only by telephone, 1 was an inpatient elsewhere, and 1
as in prison. By 1 year, there were a further 3 deaths, 10 allowed
nly follow-up by telephone, 4 were in hospital or prison, and 1
ailed to attend, thus leaving a total of 132 patients (60 Toronto and
2 Perimount) who underwent echocardiography. Measurements
ere made as recommended by the American Society of Echocar-
iography E10 over 3 cycles in sinus rhythm or over 6 cycles in
trial fibrillation. Regurgitant jets were localized and then graded
y a combination of the diameter of the base of the jet, and the
ensity and slope of the aortic regurgitant signal were recorded by
sing continuous wave Doppler imaging. Moderate regurgitation
as defined by a jet height between 25% and 60% of the outflow
iameter with a pressure half-time longer than 400 milliseconds.
ild regurgitation was defined by a jet height less than 25% of the
utflow diameter and a complete, low-intensity continuous wave-
orm with a pressure half-time longer than 400 milliseconds.
rivial regurgitation was defined by a thin low-momentum jet
nding close to the valve with an incomplete continuous wave-
orm. No jet in this study was severe.
alculations
he following calculations were performed: effective orifice area
TABLE 1. Demographic comparison of patients actually
receiving Toronto or Perimount valves
Variable
Toronto
(n  75)
Perimount
(n  85)
Age, y, mean (range) 72 (61-85) 72 (54-84)
Male/female 38:37 44:41
Height (cm) 165 (10.7) 166 (9.5)
Weight (kg) 71.1 (15.7) 74.8 (14)
BSA (kg/m2) 1.78 (0.23) 1.82 (0.19)
Etiology
Aortic stenosis 63 69
Aortic regurgitation 5 11
Mixed 3 2
Previous aortic valve replacement 4 3
Associated procedures
Coronary bypass grafts 30 26
Aortic root replacement 1 0
Preoperative NYHA class
I 2 7
II 14 20
III 37 32
IV 22 26
Data are mean (SD) unless otherwise noted. BSA, Body surface area;
NYHA, New York Heart Association.EOA) was calculated by the continuity equation:
and Cardiovascular Surgery ● Volume 131, Number 4 879
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A
CDEOA (cm2) CSA VTI1 ⁄ VTI2,
here CSA is the LV outflow cross-sectional area (square centi-
eters) calculated from the diameter. Assuming a circular cross
ection, VTI1 is the subaortic velocity integral (centimeters), and
TI2 is the aortic velocity integral (centimeters). The peak pres-
ure difference (P) across the aortic valve is
Peak P (mm Hg) 4 (v22 v12),
here v2 is the transaortic peak velocity (meters per second) and
1 is the subaortic peak velocity (meters per second). The mean P
cross the aortic valve is
Mean P (mm Hg) aortic mean P subaortic mean P,
nd
LV mass (g) 0.83 (LVDD IVS PW)3 LVDD3 0.6,
here LVDD is LV diastolic diameter, IVS is interventricular
eptum; and PW is posterior wall.
Effective orifice area and LV mass were both indexed to
ody-surface area. Thresholds for LV hypertrophy by using this
ethod are 134 g/m2 for men and 110 g/m2 for women.E11
linical Events
atients were interviewed at their 3- to 6-month and 1-year visits.
he definitions used were as recommended by The Society of
horacic Surgeons/The American Association for Thoracic Sur-
ery guidelines.E12 If the exact timing of an event was not
nown, it was taken as perioperative if noted at the immediate
ostoperative visit. It was recorded as at the midpoint between
visits if absent at the first and present at the second. Dys-
hythmic deaths after recovery from the anesthetic but before
ischarge were included as valve related. Dysrhythmias after
urgery were not included as complications if already apparent
efore surgery.
nalysis
he mean and standard deviation values were calculated for
ariables that were normally distributed and as the median
nd range for those that were skewed. Clinical events were
ABLE 2. Hemodynamic function on echocardiography at
ariable Toronto
VOT diameter (cm) 2.00 (0.1
ortic peak velocity at 3-6 mo (m/s) 2.07 (0.4
ortic peak velocity at 1 y (m/s) 2.10 (0.4
ean pressure decrease at 3-6 mo (mm Hg) 7.54 (3.6
ean pressure decrease at 1 y (mm Hg) 7.81 (3.6
ffective orifice area at 3-6 mo (cm2) 1.58 (0.4
ffective orifice area at 1 y (cm2) 1.58 (0.4
OAI at 3-6 mo (cm2/m2) 0.89 (0.2
OAI at 1 y (cm2/m2) 0.88 (0.2
I, Confidence interval; LVOT, left ventricular outflow tract; EOAI, effectivxpressed as a proportion of the entire population, whereas m
80 The Journal of Thoracic and Cardiovascular Surgery ● Aprihe incidence of regurgitation was expressed as a proportion
f those having echocardiograms. Comparisons were made
etween valve types by using the unpaired t test or non-
arametric Mann-Whitney U test as appropriate, with anal-
ses both by intention to treat and actual valves implanted.
he 2 valve types were also compared on changes between
uccessive studies. The incidence of regurgitation was com-
ared by using the Fisher exact test. Analyses were per-
ormed with the SPSS version 11.5.1 for Windows (SPSS
nc, Chicago, Ill).
esults
eneral and Hemodynamic Data
emographic characteristics in the 2 groups were similar
Table 1). The mean size implanted in the Toronto group
as 24.7 (SD, 2.69), and the mean size of Toronto that
ould have been implanted in the Perimount group was also
4.7 (SD, 2.09). Similarly, the mean size implanted in the
erimount group was 24.7 (SD, 2.17), and the mean Peri-
ount that would have been implanted in the Toronto group
as 24.8 (SD, 2.51). The hemodynamic results for each
alve type actually implanted according to label size at 3 to
 months are given in Tables E1 and E2, and those at 1 year
re given in Tables E3 and E4.
Results were similar whether analyzed by intention to
reat or actual valves implanted. They were also similar
hether predischarge, 3- to 6-month, or 1-year results were
sed. For this reason, 95% confidence intervals and P values
re given only for the actual treatment comparison at 3 to 6
onths and 1 year (Table 2). There were no significant
ifferences in any hemodynamic measurements.
The incidence of regurgitation through the valve at 3 to
months was 3 (5%) for the Toronto and 6 (8.3%) for the
erimount (Figure e1). There were no statistically signifi-
ant differences between the groups in the incidence of
egurgitation at 3 to 6 months or 1 year. There was para-
rosthetic regurgitation in 5 (7%) of the surviving Peri-
6 months and 1 year
Perimount
95% CI of the
difference P value
2.07 (0.17) 0.13, 0.12 .746
2.01 (0.4) 0.1, 0.2 .359
2.05 (0.41) 0.1, 0.2 .539
7.42 (3.59) 1.1, 1.3 .850
7.60 (3.75) 1.1, 1.5 .738
1.66 (0.49) 0.24, 0.09 .377
1.66 (0.49) 0.24, 0.08 .334
0.90 (0.26) 0.10, 0.07 .775
0.90 (0.26) 0.11, 0.06 .537
ce area index.3 to
9)
0)
1)
5)
7)
9)
5)
6)
2)ount group and none with Toronto valves.
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A
CDV Function and Mass
here was a decrease in the LV mass index at 3 to 6 months
or the Toronto by a mean of 6.7%, from 224 g/m2 (79 g/m2)
o 188 g/m2 (85 g/m2). For the Perimount, there was a
ecrease by a mean of 12%, from 249 g/m2 (76 g/m2) to 199
/m2 (62 g/m2; P  .43). At 1 year, there was a decrease
rom preoperative values by 11%, to 177 g/m2 (75 g/m2) for
he Toronto, and 20%, to 182 g/m2 (57 g/m2), for the
erimount group (P  .21). There were no differences in
he 2 valve types in terms of LV diastolic diameter or
ractional shortening.
linical Events
here were 7 (4.4%) deaths before 30 days and 13 (8.1%)
eaths in total in the first year (Table E5). There was no
tatistically significant difference between the 2 valve types.
here were 9 (5.6%) early complications, 6 cerebrovascular
vents (3 in each group), 2 gastrointestinal bleeds (1 in each
roup), and 1 paraprosthetic regurgitation in the Perimount
roup. There were 15 (9.4%) complications between 30
ays and 1 year, 8 cerebrovascular events (4 in each group),
gastrointestinal bleed in the Perimount group, 4 parapros-
hetic leaks in the Perimount group, an acquired ventricular
eptal defect in the Perimount group, and a fistula between
he aorta and right atrium in the Toronto group. The 4
araprosthetic regurgitant jets and the ventricular septal
efect were not noted on the predischarge studies, although
hese were of suboptimal image quality. There were no
tatistically significant differences in the incidence of death
r nonfatal complications up to 5 years. Between 1 and 5
ears, there were 6 deaths and 4 nonfatal complications in
oth groups.
iscussion
n the absence of a stent and sewing ring, there should be
ore space available for flow in a stentless valve. It is
herefore expected to be hemodynamically superior to an
quivalent stented valve intended for implantation in a
atient annulus of the same diameter. However, this study
howed no significant hemodynamic difference between the
tentless Toronto and the stented Perimount valve in a
andomized comparison in 160 patients.
revious Work
n early case-controlled study showed significant differ-
nces between the Toronto stentless and Hancock II stented
orcine valve at every labeled size.E3 These results were
onfirmed in small nonrandomized studiesE13,E14 and in
nother larger nonrandomized studyE4 in which the mean
ffective orifice area for 36 stentless Toronto valves was 1.9
m2, compared with 1.5 cm2 for 23 Carpentier-Edwards or
ancock II stented porcine valves. However, these results
ust be interpreted carefully because the labeled size may s
The Journal of Thoraciciffer from the diameter of the patient tissue annulus.E8 It
ay, therefore, be inappropriate to compare valves of the
ame labeled size if they are of different design.
Randomization should avoid this problem because the
omparison is then made by using the patient rather than
he labeled size as the standard. A prospective randomized
tudyE6 compared the stented porcine Carpentier-Edwards
alve with either the Toronto or Freestyle stentless valve.
he peak transaortic peak velocity was 2.3 m/s in the stentless
nd 2.5 m/s in the stented valves after surgery. By 6
onths, these figures were 2.2 and 2.4 m/s, respectively.
he difference was not statistically significant immediately
fter surgery, but it was at 6 months. Another randomized
omparisonE7 of stentless (Toronto or Biocor) and stented
Hancock II) valves showed a statistically nonsignificant trend
n favor of the stentless valves. However, neither of these 2
tudiesE6,E7 corrected for flow or used flow-independent
ormulas. Cohen and colleaguesE15 compared 99 patients
andomized to either a Toronto or Perimount valve by using
ffective orifice area by the continuity equation, which is
elatively flow independent. Unlike our study’s aim, their
ain aim was to compare regression of LV hypertrophy, the
atients were randomized only after suitability was deter-
ined for both types of valve, and more than 1 surgeon
mplanted the valves. Nonetheless, effective orifice area and
ean gradient were similar in both valves at 3 months and
year.
easons for Differences
ur results according to labeled size were similar to most of
he literature for the Perimount,E15,E16 although they were
etter than results in studiesE17 that used the modified
ernoulli equation studied at a delay after surgery. Our
esults for the Toronto were also similar toE15,E18 or better
hanE19 results in the literature.
Our results for the comparison of the 2 valve types need
ot be surprising. Although stentless porcine valves tend to
e classed with homografts, the Toronto valve could be
elatively obstructive compared with a normal native valve
s a result of the thickness of the porcine root with its
overing of Dacron, the muscle bar associated with the right
oronary artery, and the modification of leaflet physiology
s a result of preservation in glutaraldehyde. We also com-
ared it with a bovine pericardial rather than a porcine stented
alve. There is some evidence for better hemodynamic func-
ion in pericardial compared with porcine valves.E1,E20
Furthermore, comparisons may be affected by surgical
ethods, including suture techniques, the use of pledgets,
he positioning of the valve relative to the annulus, the use
f procedures to enlarge the aortic root, and the method of
izing. We did not need to enlarge the aorta, whereas others
id.E7 We used continuous sutures, which tended to hold the
tented valve in a supra-annular position and enabled us to
and Cardiovascular Surgery ● Volume 131, Number 4 881
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A
CDmplant a larger valve than would be possible in an intra-
nnular position. This difference in positioning is reflected
y the fact that in our study the median labeled size was
4.7 for both the Toronto and Perimount. In other studies,
he labeled size of the stentless valve was larger than that of
he stented comparator valve: for example, 26.3 versus 22.9E15
r 26.3 versus 24.3.E2 The alternative explanation, that we
ndersized the Toronto, is unlikely because our labeled size
as similar to that in these other studies.E5-E7,E13-E15 Sizing
or the Toronto valve was undertaken in all patients at the
inotubular junction as originally recommended by David
nd associates.E9 We did not enlarge the sinotubular junc-
ion in those patients in whom sizing at the annulus might
ave permitted implantation of a larger valve.
Comparisons may also be affected by the timing of the
chocardiographic study after surgery. The aortic root swells
round the stentless valve immediately after surgery, prob-
bly as a result of edema and hematoma. This swelling
esolves and leads to an increase in the effective orifice area
y approximately 0.2 cm2 or occasionally as much as 0.5
m2 after 3 to 6 months,E18,E21 although we, in common
ith others,E15 showed no difference. In fact, an increase in
alve area with time has also been shown for the Perimount
alve,E15 thus suggesting that factors common to all types
f valve, such as changes in flow, may be partly responsible.
egurgitation and Clinical Event
ur study agrees with previous workE1,E22 in showing mild
r moderate regurgitation through 10% of Toronto and 13.9%
f Perimount valves at 1 year. By comparison, Dellgren and
olleaguesE16 showed mild regurgitation in 30% of Perimount
alves at a mean of 67 months after surgery, and Banbury
nd colleaguesE17 showed mild regurgitation in 19% and
oderate regurgitation in 8% at 3 years. Similar degrees of
egurgitation were reported in 9% to 21%E18,E23-E25 of
oronto valves, whereas severe regurgitation was shown in
.2%.E24 Mild regurgitation is increasingly seen as the im-
ge quality and sensitivity of echocardiography systems
mprove and may be normal. Trivial regurgitation may even
e seen on occasion in normal native valves. Although we
re not aware of any evidence that such minor regurgitation
as any clinical significance—for example, as a risk factor
or endocarditis—no long-term confirmation of this exists.
urthermore, the incidence of regurgitation may increase
ith time in Toronto valves as a result of dilatation of the
ortic root,E26 although this was not found in the limited
ollow-up in this study. We found paraprosthetic regurgita-
ion only in the Perimount, although in each case it was
linically unimportant.
There were no statistically significant differences between
he Toronto and Perimount valves in clinical events or
omplications other than paraprosthetic regurgitation. This
as true of the complete cohort at 1 year and the smaller t
82 The Journal of Thoracic and Cardiovascular Surgery ● Apriumber followed up to 5 years. There was no valve failure
nd no thrombosis or endocarditis. These results are similar
o those of most previously reported studies.E16,E27,E28 In
he study of Desai and colleagues,E29 there was 1 thrombo-
is of a Toronto valve 1 month after implantation, 1 failure
f a Toronto at 23 months, and 12 failures at an average of
6 months, thus giving an actuarial freedom from structural
ailure of 98.8% at 5 years and 77.9% at 10 years.
The degree of regression of LV hypertrophy and mea-
ures of LV systolic function were no different at 3 to 6
onths or 1 year for the 2 valve types. Other studies have
hown no difference in LV mass regressionE15,E27 or a
enefit in favor of the Toronto or other stentless valve.E6
his result is in keeping with the similarity in hemodynamic
unction between the 2 valves. However, there was limited
egression of LV mass in both groups, with a mass index of
77 g/m2 (SD, 75 g/m2) for the Toronto and 182 g/m2 (SD,
7 g/m2) for the Perimount at 1 year. The factors determin-
ng LV mass regression are complex. The degree of regres-
ion depends less on replacement valve function than on the
egree of preoperative hypertrophy, its duration before sur-
ery, and the blood pressure after surgery.E30
imitations
here was complete follow-up for clinical events up to 1
ear. However, numbers followed beyond 5 years were
mall. A small difference between the valves cannot there-
ore be excluded. The study continues, and fuller data in the
id-term and long-term will be reported. Randomization
as performed at the start of operation, and there were 11
rossovers for technical reasons, usually because of exten-
ive calcification or annular destruction. However, hemody-
amic results were not materially affected, whether analysis
as by intention-to-treat or actual valves implanted. There
s increasing interest in the use of stentless valves as whole-
oot replacements. This would be expected to improve the
emodynamic comparison against a stented valve, and our
onclusions about the subcoronary Toronto might not apply
o all stentless valves. It may often be inappropriate to
ompare stentless and stented valves as if these were uni-
orm classes. It is clear that differences in performance may
xist depending on constituent materials, the method of man-
facturing, label sizes, and implantation techniques, and
hese differences need to be given in comparative studies.
onclusion
his study showed no statistically significant difference in
emodynamic function, regression of LV hypertrophy, or
linical events at a year between the stentless porcine To-
onto valve implanted in a subcoronary position and the
tented bovine pericardial Perimount valve, which, in this
tudy, was mounted in a supra-annular position. Parapros-
hetic regurgitation was seen only for the Perimount valve.
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